Please upgrade your browser.
The Onconeural Antigen cdr2 Is a Novel APC/C Target that Acts in Mitosis to Regulate C-Myc Target Genes in Mammalian Tumor Cells
Cdr2 is a tumor antigen expressed in a high percentage of breast and ovarian tumors and is the target of a naturally occurring tumor immune response in patients with paraneoplastic cerebellar degeneration, but little is known of its regulation or function in cancer cells. Here we find that cdr2 is cell cycle regulated in tumor cells with protein levels peaking in mitosis.
Studying patients with kidney cancer, a team of researchers at Washington University School of Medicine in St. Louis has identified a pair of proteins excreted in the urine that could lead to earlier and more accurate diagnosis of the disease.
In this review, we discuss the use of molecularly-targeted kinase inhibitors in the treatment of renal-cell carcinoma and identify the next generation of kinase inhibitors that show promise for treatment.
The trial will determine whether BNC105 is effective in the treatment of progressive metastaticrenal cell carcinoma, either in combination with or following Afinitor (also known asEverolimus) treatment in patients who have disease progression following treatment withtyrosine kinase inhibitors such as Sutent or Nexavar.
And it happened by accident. Right there inside chemistry labs in a science building along Euclid Avenue.
Ask Dr. DeSilva Internet radio program: Sarah Wise Miller, chairman of the Board of Directors of the Kidney Cancer Association and a ten-year survivor of Renal Cell Carcinoma joins the show to discuss the do's and dont's of managing your Kidney cancer treatment.
According to Dr. Cohen, Pazopanib has been previously used in humans extensively as an oral agent for the treatment of renal cell carcinoma.
Mr. Cameron said: "Other European countries are giving people longer, happier lives with cancer than we are. Thousands whose doctors would like them to have a drug will get it."
Witney MP and Conservative Party leader, David Cameron, met campaigners for kidney cancer drugs in Witney, where he outlined a plan for a cancer drugs fund.
This fun, family-friendly event, May 1, 2010, is held to honor Michael J. Garner, retired Tulsa Police Officer who lost his battle with kidney cancer in 2008.
|Powered by NeonCRM|